Patent search ap:("BRISTOL-MYERS SQUIBB COMPANY") AND inv:"Alaric J. Dyckman" Page 7

61.

发明申请
DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS 有权

公开(公告)号：US20210292300A1

公开(公告)日：2021-09-23

申请号：US16321616

申请日：2017-07-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman , Dharmpal S. Dodd , Christopher P. Mussari , Tasir S. Haque , Michael A. Poss , Louis J. Lombardo , John E. Macor , Laxman Pasunoori , Sreekantha Ratna Kumar

IPC: C07D401/14 , C07D401/04 , C07D405/14 , C07D417/14 , C07D451/02 , C07D409/14 , C07D413/14 , A61P37/06

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1; R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

62.

发明授权
Oxime ether compounds 有权

公开(公告)号：US11059784B2

公开(公告)日：2021-07-13

申请号：US16636662

申请日：2018-08-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman , Ling Li , T. G. Murali Dhar , Hai-Yun Xiao

IPC: C07D213/53 , C07D207/12 , A61P37/06 , C07D211/96 , C07D211/40

Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is —OH or —OP(O)(OH)2; L is —CR3═N—O—CRaRa— or CRaR—O—N═CR3; L2 is a bond, —C(O)—, or S(O)2—; and R2, R3, Ra, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

63.

发明授权
Substituted bicyclic compounds 有权

公开(公告)号：US11058696B2

公开(公告)日：2021-07-13

申请号：US16879824

申请日：2020-05-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman , T. G. Murali Dhar , Hai-Yun Xiao , John L. Gilmore , Michael G. Yang , Zili Xiao , David Marcoux

IPC: A61K31/695 , C07F7/08 , A61K31/135 , C07D215/14 , C07D241/04 , C07C323/29 , C07C251/38 , C07C251/42 , C07C251/44 , C07D209/46 , C07D213/38 , C07C275/26 , C07C217/74 , C07C323/25 , C07C235/46 , C07F9/54 , C07F9/572 , C07F9/09 , C07C215/42 , C07C217/52 , C07C217/58 , C07C219/24 , C07C233/41 , C07C233/65 , C07C251/50 , C07C251/52 , C07C251/54 , C07C271/34 , C07C317/28 , C07C317/32 , C07C321/16 , C07C321/22 , C07C321/28 , C07D213/32 , C07D213/69 , C07D213/70 , C07D215/12 , C07D217/24 , C07D231/12 , C07D231/20 , C07D239/26 , C07D241/12 , C07D277/24 , C07D305/08 , C07D309/06 , C07D309/12 , C07D311/58 , C07D311/76 , C07D319/20 , C07D333/16 , C07F9/117 , C07F9/62 , C07F9/6503 , C07F9/6509 , C07F9/655 , C07F9/6553 , A61K31/137 , A61K31/15 , A61K31/165 , A61K31/166 , A61K31/17 , A61K31/222 , A61K31/24 , A61K31/27 , A61K31/337 , A61K31/351 , A61K31/352 , A61K31/381 , A61K31/415 , A61K31/4174 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/47 , A61K31/4965 , A61K31/505 , A61K31/661

Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

64.

发明申请
[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS 审中-公开

公开(公告)号：US20200038374A1

公开(公告)日：2020-02-06

申请号：US16653297

申请日：2019-10-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman , Dharmpal S. Dodd , Tasir Shamsul Haque , Louis J. Lombardo , John E. Macor , Christopher P. Mussari , Laxman Pasunoori , Sreekantha Ratna Kumar , Trevor C. Sherwood , Shoshana L. Posy , Ramesh Kumar Sistla , Subramanya Hegde , Anupama Kandhi Ramachandra Reddy

IPC: A61K31/4196 , C07D249/00 , A61K31/437 , A61K31/4427 , A61K45/06 , C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

65.

发明授权
4-azaindole compounds 有权

公开(公告)号：US10544143B2

公开(公告)日：2020-01-28

申请号：US16222145

申请日：2018-12-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman , Dharmpal S. Dodd , Christopher P. Mussari , Sreekantha Ratna Kumar

IPC: C07D519/00 , A61K31/437 , C07D471/04 , C07D491/107 , C07D471/08 , A61P25/00 , A61P29/00 , A61P19/02 , C07D495/10

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

66.

发明授权
[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds 有权

公开(公告)号：US10478424B2

公开(公告)日：2019-11-19

申请号：US16042116

申请日：2018-07-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman , Dharmpal S. Dodd , Christopher P. Mussari , Laxman Pasunoori , Sreekantha Ratna Kumar

IPC: A61K31/4196 , A61K31/437 , A61K31/4427 , A61K45/06 , C07D249/00 , C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

67.

发明申请
SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS 审中-公开

公开(公告)号：US20190218193A1

公开(公告)日：2019-07-18

申请号：US16329399

申请日：2017-08-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： David Marcoux , Hai-Yun Xiao , T.G. Murali Dhar , Alaric J. Dyckman

IPC: C07D277/84 , C07D261/20 , C07D333/74 , C07D417/10 , C07F9/117 , C07D417/14

CPC classification number: C07D277/84 , C07D261/20 , C07D277/60 , C07D333/50 , C07D333/74 , C07D417/06 , C07D417/10 , C07D417/14 , C07F9/117 , C07F9/65324 , C07F9/6541 , C07F9/655354

Abstract: Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV) or salts thereof, wherein R2 is —OH or —OP(O)(OH)2; and R1 is defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.